Physician
Bethpage Medical, PLLC
Bethpage Medical, PLLC was paid $32.08M by Medicaid between Jan 2018 and Dec 2024, across 124 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 13% of everything it billed.
33Billing provider infoBETHPAGE MEDICAL, PLLC
GARDEN CITY, NY 11530
GARDEN CITY, NY 11530
33aNPI1205074739assigned 01/21/2009
33bProvider typeObstetrics & Gynecology Physician
28Total paid$32.08M
24GClaims761,331
24DCodes billed124
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Obstetrics & Gynecology Physician providers in New York
Rank by total paid#2 of 762
Median peer was paid$22K
This provider vs. median1,481×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 51,497 | $1.98M | |
| 2019 | 63,521 | $2.44M | |
| 2020 | 83,520 | $3.72M | |
| 2021 | 120,319 | $5.23M | |
| 2022 | 136,743 | $5.97M | |
| 2023 | 163,534 | $6.88M | |
| 2024incomplete | 142,197 | $5.86M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13% | 55,516 | 50,476 | $4.06M |
| 76830 | Ultrasound, transvaginal | 11% | 42,176 | 40,967 | $3.51M |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | 8.8% | 30,478 | 25,782 | $2.82M |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | 7.7% | 33,557 | 26,621 | $2.49M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 5.9% | 37,910 | 29,497 | $1.90M |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | 5.0% | 17,335 | 17,307 | $1.61M |
| 76820 | 4.3% | 39,140 | 24,395 | $1.37M | |
| 58558 | 3.8% | 994 | 993 | $1.22M | |
| 76819 | Fetal biophysical profile; without non-stress testing | 3.7% | 14,987 | 11,019 | $1.17M |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 3.3% | 25,018 | 24,548 | $1.06M |
| 76818 | 3.1% | 9,680 | 5,283 | $986K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | 3.0% | 12,480 | 10,396 | $958K |
112 more codes
| 99385 | 2.6% | 7,811 | $819K | |
| 81513 | 2.1% | 6,518 | $676K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | 2.1% | 6,532 | $665K |
| 76801 | 1.9% | 7,780 | $624K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 1.8% | 23,864 | $562K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 1.7% | 23,849 | $560K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.6% | 21,911 | $524K |
| 59400 | Routine obstetric care including antepartum care, vaginal delivery, and postpartum care | 1.0% | 129 | $329K |
| 81025 | <1% | 75,566 | $312K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 2,523 | $308K |
| 76813 | <1% | 2,820 | $301K | |
| 99386 | <1% | 2,034 | $245K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 9,189 | $240K |
| 59426 | <1% | 215 | $214K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 2,090 | $210K |
| 59430 | <1% | 740 | $191K | |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 9,947 | $189K |
| 76376 | <1% | 10,057 | $155K | |
| 81002 | <1% | 79,039 | $152K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,187 | $116K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,617 | $105K |
| 76857 | <1% | 2,887 | $91K | |
| 57454 | <1% | 549 | $90K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,525 | $88K |
| 87481 | <1% | 3,193 | $76K | |
| 00952 | <1% | 790 | $69K | |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 386 | $59K |
| 84144 | <1% | 3,004 | $54K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,033 | $44K |
| 86780 | <1% | 3,762 | $40K | |
| 82670 | <1% | 1,664 | $40K | |
| 59840 | <1% | 158 | $39K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 49,507 | $38K |
| 84702 | <1% | 3,282 | $38K | |
| 82626 | <1% | 1,620 | $35K | |
| 59510 | <1% | 12 | $34K | |
| 84146 | <1% | 1,649 | $28K | |
| 83001 | <1% | 1,631 | $27K | |
| 83002 | <1% | 1,573 | $26K | |
| 86703 | <1% | 2,209 | $25K | |
| 88342 | <1% | 600 | $25K | |
| 84439 | <1% | 3,043 | $24K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,570 | $24K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 335 | $22K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 228 | $21K |
| 88341 | <1% | 618 | $21K | |
| 59409 | Vaginal delivery only (with or without episiotomy and/or forceps) | <1% | 27 | $20K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 952 | $19K |
| 01966 | <1% | 195 | $18K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,262 | $16K |
| 80053 | Comprehensive metabolic panel | <1% | 1,578 | $14K |
| 88141 | <1% | 809 | $14K | |
| 87625 | <1% | 455 | $13K | |
| 84481 | <1% | 1,317 | $12K | |
| 76641 | <1% | 152 | $12K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 179 | $12K |
| 99384 | <1% | 101 | $11K | |
| 86696 | <1% | 841 | $11K | |
| Q0091 | Screening papanicolaou smear; obtaining, preparing and conveyance of cervical or vaginal smear to laboratory | <1% | 943 | $11K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,873 | $10K |
| 93975 | <1% | 48 | $10K | |
| 86762 | <1% | 797 | $9K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 60 | $9K |
| 87563 | <1% | 370 | $8K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 225 | $8K |
| 86765 | <1% | 703 | $7K | |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 239 | $7K |
| 58301 | <1% | 63 | $7K | |
| 82607 | <1% | 583 | $6K | |
| 86706 | <1% | 748 | $6K | |
| 93976 | <1% | 162 | $6K | |
| 86735 | <1% | 701 | $6K | |
| 86787 | <1% | 538 | $5K | |
| 80074 | <1% | 190 | $4K | |
| 86704 | <1% | 456 | $4K | |
| 82746 | <1% | 373 | $4K | |
| 80061 | Lipid panel | <1% | 569 | $4K |
| 76821 | <1% | 49 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 2,184 | $4K |
| 86708 | <1% | 361 | $3K | |
| 84480 | <1% | 502 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 601 | $3K |
| 86777 | <1% | 220 | $3K | |
| 00940 | <1% | 28 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,472 | $2K |
| 0012A | <1% | 66 | $2K | |
| 0011A | <1% | 62 | $2K | |
| 80050 | General health panel | <1% | 101 | $2K |
| 88304 | <1% | 163 | $2K | |
| 58300 | <1% | 25 | $2K | |
| 84403 | <1% | 62 | $1K | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 36 | $1K |
| 82950 | <1% | 287 | $1K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 36 | $1K |
| 83540 | <1% | 202 | $929.85 | |
| 83550 | <1% | 183 | $902.63 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,319 | $902.01 |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 12 | $881.42 |
| 86695 | <1% | 198 | $793.09 | |
| 81003 | <1% | 456 | $702.31 | |
| S0190 | Mifepristone, oral, 200 mg | <1% | 13 | $516.05 |
| 82947 | <1% | 137 | $472.23 | |
| 84436 | <1% | 82 | $319.08 | |
| 82040 | <1% | 43 | $188.69 | |
| 82951 | <1% | 13 | $117.87 | |
| 99000 | <1% | 31,146 | $85.33 | |
| 83615 | <1% | 16 | $73.23 | |
| 84479 | <1% | 48 | $67.44 | |
| 84550 | <1% | 16 | $61.26 | |
| 82465 | <1% | 12 | $47.85 | |
| 84270 | <1% | 66 | $31.77 | |
| 91301 | <1% | 88 | $0.25 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTERRANI, MICHAEL (OWNER)